FDA appropriations
This article was originally published in The Gray Sheet
Executive Summary
Device center program funding levels increase $13.9 mil. from FY 2001 under Senate Appropriations Committee bill (S 1191). The amount is consistent with FDA estimates for bringing review times within statutory requirements in the short term. The measure, adopted by the Senate Oct. 25, earmarks $178.8 mil. for CDRH and for related field activities in the Office of Regulatory Affairs. The House version, passed in June, includes roughly $179.5 mil. for CDRH (1"The Gray Sheet" June 18, 2001, In Brief)...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.